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Pharmacodynamics and safety of lefradafiban, an
oral platelet glycoprotein IIb/IIIa receptor
antagonist, in patients with stable coronary artery
disease undergoing elective angioplasty
K M Akkerhuis, M J B M van den Brand, C van der Zwaan, H O J Peels, H Suryapranata,
L R van der Wieken, J Stibbe, J HoVmann, T Baardman, J W Deckers, M L Simoons
Abstract
Objective—Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor
antagonist. The present phase II study aimed to determine the dose of lefradafiban that provides
80% blockade of the glycoprotein IIb/IIIa receptors by fradafiban, and to study the
pharmacodynamics and safety of diVerent doses in patients with stable angina undergoing
angioplasty.
Design—A double blind, placebo controlled, dose finding study.
Setting—Four academic and community hospitals in the Netherlands.
Patients—64 patients with stable coronary artery disease undergoing elective percutaneous
transluminal coronary angioplasty.
Interventions—30 mg, 45 mg, and 60 mg of lefradafiban three times daily or placebo was given
for 48 hours.
Main outcome measures—The primary safety end point was the occurrence of bleeding, clas-
sified as major, minor, or insignificant according to the thrombolysis in myocardial infarction
(TIMI) criteria. EYcacy indices included per cent fibrinogen receptor occupancy (FRO), ex vivo
platelet aggregation, and plasma concentrations of fradafiban.
Results—Administration of lefradafiban 30, 45, and 60 mg three times daily resulted in a dose
dependent increase in median FRO levels of 71%, 85%, and 88%, respectively. Inhibition of
platelet aggregation was closely related to FRO. There were no major bleeding events. The 60 mg
lefradafiban group had a high (71%) incidence of minor and insignificant bleeding. The
incidence of bleeding was 44% in the 30 mg and 45 mg groups, compared with 9% in placebo
patients. Puncture site bleeding was the most common event. The odds of bleeding increased by
3% for every 1% increase in FRO.
Conclusions—Lefradafiban is an eVective oral glycoprotein IIb/IIIa receptor blocker. The clini-
cal eVectiveness of doses up to 45 mg three times daily should be investigated.
(Heart 2001;85:444–450)
Keywords: platelet aggregation inhibitors; glycoprotein IIb/IIIa blockers; lefradafiban; angioplasty
Platelet adhesion, activation, and aggregation
are pivotal events in the process leading to cor-
onary thrombosis in patients with unstable
coronary artery disease.1 This process is also
activated during percutaneous transluminal
coronary angioplasty (PTCA) by local vascular
injury, which exposes circulating platelets to
various prothrombotic stimuli within the sub-
endothelium.2 3 The final common pathway to
coronary thrombus formation involves aggre-
gation of platelets through cross linkage of their
glycoprotein (GP) IIb/IIIa receptors by the
primary binding ligand fibrinogen.4
Several inhibitors of the GP IIb/IIIa receptor
have been developed. The monoclonal anti-
body c7E3 (abciximab) has been shown to
reduce the incidence of death and myocardial
infarction in patients undergoing PTCA, with
or without stent deployment.5–8 Small mol-
ecules (eptifibatide, tirofiban) given intrave-
nously also reduce complications associated
with PTCA, although their eVects were of bor-
derline significance.9 10 These intravenous GP
IIb/IIIa receptor blockers have also recently
been shown to reduce the incidence of death,
recurrent myocardial infarction, and recurrent
ischaemia in patients with unstable angina or
non-ST-segment elevation myocardial
infarction.11–13
The clinical use of monoclonal antibodies
and small molecules as GP IIb/IIIa receptor
blockers is limited to the treatment of acute
episodes of unstable angina, or treatment dur-
ing coronary procedures, as oral administration
is not feasible. Lefradafiban (Boehringer Ingel-
heim, Germany) is an orally active prodrug
which is metabolised in two steps to fradafiban,
an intravenously active, non-peptide GP IIb/
IIIa receptor inhibitor.14 In studies with healthy
volunteers, both fradafiban and lefradafiban
led to a reversible and dose dependent
inhibition of platelet aggregation.14
Our aim in this first phase II study was to
determine the dose regimen of lefradafiban
that provides 80% blockade of the platelet GP
IIb/IIIa receptors by fradafiban, as well as to
study the pharmacodynamics and safety of dif-
ferent doses in patients with stable coronary
artery disease undergoing elective PTCA, in
order to select the appropriate range of dose
regimens for subsequent larger studies.
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Methods
STUDY POPULATION
Patients aged between 18 and 80 years with
stable coronary artery disease were eligible for
enrolment if they were scheduled for elective
PTCA. Patients were excluded if they suVered
from unstable angina or if there was a total
occlusion of the vessel to be treated. Other cri-
teria for exclusion included myocardial infarc-
tion within the preceding 14 days; planned
stent implantation; major surgery or trauma
within the preceding six weeks; any history of
cerebrovascular haemorrhage or haemorrhagic
diathesis, cardiopulmonary resuscitation, or
complicated puncture of a major vein or artery
within the preceding six weeks; retinopathy
grade 3 or greater; gastrointestinal or genito-
urinary bleeding within the preceding six
weeks; peptic ulcer disease; platelet count
< 100 × 109/l; uncontrolled hypertension
(systolic blood pressure > 200 mm Hg and/or
diastolic blood pressure > 100 mm Hg); cur-
rent treatment with oral anticoagulants or any
antiplatelet agent other than acetylsalicylic
acid, including any non-steroidal anti-
inflammatory agent; pregnant or nursing
women or women not using medically ap-
proved means of contraception; known hepatic
or renal insuYciency; or any other concomitant
serious illness which would limit life expect-
ancy or interfere with the study end points.
The study protocol was reviewed and
approved by each hospital’s institutional review
board, and informed consent was obtained
from each patient before participation in the
trial.
STUDY DESIGN AND DOSE SELECTION
The initial protocol envisaged a dose escala-
tion, starting with lefradafiban 60 mg three
times daily or placebo, and increasing to 75 mg
and 90 mg three times daily. Based on phase I
data in healthy volunteers, the latter dose was
expected to achieve fibrinogen receptor occu-
pancy (FRO) levels of more than 80%.14 How-
ever, after studies on the first group of 21
patients treated with lefradafiban 60 mg three
times daily had been completed, it became
apparent that this dose was associated with a
high incidence of bleeding and with FRO levels
of more than 80% (see Results). Therefore, the
dose for the next group was reduced to 30 mg
three times daily. After the safety of this
regimen had been established, a third group
was investigated receiving lefradafiban 45 mg
three times daily or placebo.
Within each dose level, patients were ran-
domised in a 4:1 ratio to receive lefradafiban or
placebo in a double blind manner. The study
drug was given as an oral solution three times a
day for two days. It was not to be taken within
two hours after or one hour before a meal. The
first dose was given two hours before the start
of the PTCA. An additional loading dose was
given 3.5 hours after the first dose, while
subsequent doses were given at eight hour
intervals.
CONCOMITANT TREATMENT
Before the start of the PTCA, all patients
received an intravenous bolus of heparin of
5000 IU, as well as an intravenous bolus of
250 mg aspirin. During the procedure, heparin
was repeated in boluses of 5000 IU after 30, 60
and, if necessary, 120 minutes. Aspirin was
continued in a dose of 100 mg daily. The use of
ticlopidine together with lefradafiban was
excluded by the protocol because no interac-
tion data were available at that time. Therefore,
if stenting was performed, the study drug was
discontinued and ticlopidine (250 mg once or
twice a day) was initiated. Other drugs were
continued as before randomisation and ad-
justed as required by the clinical status of the
patient.
CLINICAL AND LABORATORY MONITORING
A coronary angiogram was performed immedi-
ately before and after PTCA. Coronary flow
was classified according to the thrombolysis in
myocardial infarction (TIMI) study classifi-
cation by a central angiographic core labora-
tory (Cardialysis BV).15 Sheaths were removed
4–6 hours after discontinuation of the heparin
infusion and as close as possible to the next
intake of study drug, assuming that the platelet
inhibitory activity of fradafiban would be at its
nadir. Patients underwent daily clinical assess-
ment for the occurrence of bleeding complica-
tions and other adverse events as well as exten-
sive laboratory evaluation for haematology,
coagulation, and biochemistry. They returned
for a follow up visit two weeks after hospital
discharge, which was not to take place within
48 hours from first study drug administration.
Samples for determination of FRO and
plasma concentrations of fradafiban were
obtained at baseline and at 2, 4, 12, 24, 36, and
48 hours after the first dose of the study drug.
Blood for determination of FRO was stored in
a Monovette prefilled with ACD (trisodium
citrate, citric acid, dextrose). Platelet rich
plasma was prepared by centrifugation and
mixed with labelled fradafiban. After incuba-
tion and centrifugation, the supernatant as well
as the platelet pellet were counted for free
ligand in a 4 ml scintillation cocktail. Non-
specific binding was determined in the pres-
ence of unlabelled fradafiban. The specific
binding was calculated using corrections for
spillover, extracellular space, and non-specific
binding. The percentage of FRO was then cal-
culated from the specific binding data, using
corrections for receptor aYnity and dilution of
ACD.
Blood for determination of plasma frad-
afiban concentrations was drawn into tubes
with EDTA. Plasma was separated immedi-
ately by centrifugation and stored at −20°C
until analysis. Plasma concentrations of
fradafiban were measured using a validated
high performance liquid chromatographic
method with fluorescence detection.14 The
lower limit of quantification was 1 ng/ml.
Ex vivo platelet aggregation was assessed in a
subgroup of 32 patients at baseline and at 2, 4,
24, and 48 hours after study drug initiation.
Platelet aggregation was measured in citrated
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platelet rich plasma and recorded by a
Chrono-log aggregometer during a 6–8 minute
interval after induction by two agonists:
1 mmol/l ADP and 2 mg/ml collagen, respec-
tively. Results are expressed as maximum per
cent aggregation achieved in platelet rich
plasma, using platelet poor plasma as reference
of 100%.
Ivy bleeding times determined with standard
techniques were obtained at baseline and at the
end of the 48 hour treatment period. Measure-
ment of bleeding times was discontinued at 15
minutes.
SAFETY AND EFFICACY INDICES
The primary safety end point in this trial was
the occurrence of bleeding complications, clas-
sified as major, minor, or insignificant accord-
ing to the criteria of the TIMI study group.16
Major bleeding was defined as intracranial or
bleeding associated with a decrease in haemo-
globin of more than 3.1 mmol/l (5 g/dl) or a fall
in haematocrit of more than 15%. Minor
bleeding was defined as observed blood loss
with a decrease in haemoglobin of 1.9–
3.1 mmol/l (3.1–5.0 g/dl) or a fall in haemat-
ocrit of 10–15%. Spontaneous gross haema-
turia or haematemesis, as well as a decrease in
haemoglobin of 2.5–3.1 mmol/l or a fall in
haematocrit of 12–15% without an identifiable
bleeding site, were also considered to indicate
minor bleeding. Blood loss insuYcient to meet
criteria for minor bleeding was classified as
insignificant. Haemoglobin values were ad-
justed if patients received packed red blood
cells or whole blood within 48 hours of the
measurement.17
The primary eYcacy variable was the FRO
level in percentages, expressed as area under
the curve normalised per hour. Secondary eY-
cacy variables included the ex vivo platelet
aggregation and plasma concentrations of
fradafiban.
STATISTICAL ANALYSIS
Descriptive analyses of angiographic, aggrega-
tion, and safety data are presented. The associ-
ation of % FRO, expressed as area under the
curve (AUC), with the first bleeding event was
assessed using logistic regression analysis, the
null hypothesis being that the risk of bleeding
was not aVected by FRO levels. The AUC was
calculated until the first bleeding, as well as
over the whole treatment interval. The relation
between bleeding and heparin administration
as well as with the activated partial thrombo-
plastin time (aPTT) AUC was investigated
with logistic regression analysis in a similar
way.
Results
Sixty four patients were enrolled: 16 received
lefradafiban at a dose of 30 mg three times
daily, 16 received 45 mg three times daily, 21
received 60 mg three times daily, and 11
received placebo. The majority (73%) of the
patients were male (table 1). Their mean age
was 61 years (range 39–79 years). A previous
myocardial infarct was present in 15 patients
(23%), while three (5%) had undergone
coronary artery bypass surgery, and seven
(11%) had had PTCA. All patients received the
study drug and underwent PTCA as sched-
uled. The treated segments were in the right
coronary artery in 14 patients (22%), in the
circumflex coronary artery in 19 (30%), and in
the left anterior descending coronary artery in
31 (48%). Coronary flow was normal (TIMI
grade III) in 54 patients (84%). Following
PTCA, TIMI grade III flow was achieved in all
patients, except two in the placebo group
(TIMI 0), both caused by dissection. A stent
was placed in nine patients. In these patients,
the study drug was discontinued and ticlopi-
dine (250 mg once or twice a day) was begun.
PHARMACODYNAMICS AND INHIBITION OF
PLATELET AGGREGATION
Plasma concentrations of fradafiban increased
in a dose dependent manner in patients treated
with lefradafiban. Geometric means of the
maximum plasma concentration of fradafiban
at steady state were 158, 314, and 394 ng/ml
during treatment with lefradafiban 30, 45, and
60 mg three times daily, respectively (table 2).
The pharmacokinetic profile of lefradafiban
was predictable and no significant deviations
from dose proportionality were observed.
There was a close correlation between the
plasma concentrations of fradafiban and FRO
(fig 1). FRO increased in a dose dependent
manner in patients treated with lefradafiban.
Median FRO was 0% in the placebo group,
71% in the lefradafiban 30 mg group, 85% in
the lefradafiban 45 mg group, and 88% in the
lefradafiban 60 mg group (table 2). Minimum,
mean, and maximum FRO values were also
dose dependent. Plasma fradafiban concentra-
tions of 170 ng/ml were required to achieve
80% FRO (fig 1). There was little variation in
FRO within each patient (fig 2), while the
Table 1 Clinical and angiographic characteristics at baseline
Placebo
(n=11)
Lefradafiban dose (× 3 daily)
30 mg
(n=16)
45 mg
(n=16)
60 mg
(n=21)
Patient demographics
Age (years) (mean (SD)) 58 (7) 65 (8) 62 (13) 60 (12)
Male sex (n) 8 14 11 14
Diabetes (n) – 3 1 2
Hypertension (n) 2 2 6 5
Previous MI (n) 1 5 5 4
Previous PTCA or CABG (n) 1 3 3 3
Angiographic variables
Segments to be treated (n)
RCA 3 2 3 6
LAD 6 9 8 8
LCX 2 5 5 7
Perfusion grade, TIMI flow (n)
Grade 0 1 – 1 –
Grade 1 1 – – 1
Grade 2 1 2 1 2
Grade 3 8 14 14 18
Lesion type by AHA/ACC (n)
A 1 – 2 1
B1 5 3 5 4
B2 5 10 6 9
C – 3 3 5
Missing – – – 2
AHA/ACC, American Heart Association/American College of Cardiology; CABG, coronary
artery bypass grafting; LAD, left anterior descending artery; LCX, left circumflex artery; MI,
myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; RCA, right
coronary artery; TIMI, thrombolysis in myocardial infarction.
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interpatient variability was greater among
patients receiving the lower dose than among
those treated with the higher doses (fig 2 and
table 2), reflecting the plasma concentration–
FRO relation (fig 1).
Ex vivo platelet aggregation was measured in
32 patients and decreased with higher FRO
levels (fig 3). In placebo patients, platelet
aggregation was approximately 60% of normal.
Inhibition of platelet aggregation to values
below 20%, or greater than 80% inhibition,
was observed in all patients with FRO values
above 80%.
Bleeding times measured at 48 hours were in
the normal range for all patients with FRO
values below 70%, while prolonged bleeding
times were observed in the majority of patients
with higher FRO values (fig 4).
ADVERSE EVENTS
Adverse events resulting in discontinuation of
study drug treatment occurred in four patients:
angina with cardiogenic shock in one (30 mg),
leucopenia in one (30 mg), and bleeding in two
other patients, both in the 45 mg group. No
major bleeding events were reported. Minor
and insignificant bleeding complications were
frequent in the highest dose group (60 mg
three times a day), in which 15 of 21 patients
(71%) experienced such events (table 2).
There was one haematoma in the placebo
group, while bleeding was reported in seven
(44%) of 16 patients receiving lefradafiban
30 mg three times daily, as well as in seven
(44%) of 16 patients receiving lefradafiban
45 mg three times daily (table 2). Arterial and
venous puncture site bleeding was most
Table 2 EYcacy and safety end points
Placebo
(n=11)
Lefradafiban dose (× 3 daily)
30 mg
(n=16)
45 mg
(n=16)
60 mg
(n=21)
EYcacy indices
Plasma concentration of fradafiban (ng/ml)* 0 158 (27) 314 (24) 394 (22)
FRO (%)—minimum 0 54 74 78
FRO (%)—median 0 71 85 88
FRO (%)—maximum 0 80 89 95
FRO (%)—mean† 0 69 (12) 83 (6) 87 (5)
Bleeding time
At baseline (min) 3.3 4.0 4.1 5.3
After 48 hours (min) 4.4 7.8 19.2 25.0
Bleeding complications
Patients with bleeding, n (%) 1 (9) 7 (44) 7 (44) 15 (71)
Number of bleeding events (n) 1 8 9 29
Location of bleeding (n)
Vascular puncture site 1 6 6 15
Gingival – 1 2 10
Skin – 1 1 2
Haematuria – – – 2
Severity of bleeding by TIMI (n)
Major – – – –
Minor – – 1 2
Insignificant 1 8 8 27
*Mean maximum fradafiban plasma concentration at steady state (Cmax,ss) with the relative coef-
ficient of variation (%) in parentheses.
†Relative coeYcient of variation (%) in parentheses.
All FRO values are expressed as area under the curve normalised per hour. Relative coeYcient of
variation = 100 × (standard deviation/mean).
Figure 1 Relation between the plasma concentration of the
active drug fradafiban and the degree of fibrinogen receptor
occupancy (FRO).
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Figure 2 Degree of fibrinogen receptor occupancy (FRO)
during oral administration of lefradafiban (A) 30 mg, (B)
45 mg, and (C) 60 mg three times daily. Each line
represents data from an individual patient in one of the
three lefradafiban groups during 48 hours of oral treatment.
Each line is based on FRO data obtained at one of the
prespecified sample time points (baseline and 2, 4, 12, 24,
36, and 48 hours after the study drug was started).
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Figure 3 Relation between the degree of fibrinogen
receptor occupancy (FRO) and inhibition of ex vivo
platelet aggregation induced by 1 mmol/l ADP in platelet
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single time point during the 48 hours of oral treatment with
lefradafiban 30, 45, or 60 mg three times daily.
100
80
60
40
20
0
10080
FRO (%)
A
g
g
re
g
at
io
n
 (
%
)
60400 20
Oral platelet glycoprotein IIb/IIIa receptor antagonist 447
www.heartjnl.com
 on 17 October 2006 heart.bmjjournals.comDownloaded from 
common. All bleeding events occurred more
than two hours after administration of the first
dose.
By logistic regression analysis, higher values
of FRO were found to be significantly related
to an increased incidence of bleeding. The
odds of bleeding increased by a factor of 1.03
for every 1% increase in FRO (p < 0.01). The
relation between bleeding and heparin admin-
istration, as well as with the aPTT AUC, was
explored in a similar way. When heparin
administration and aPTT AUC were restricted
to observations before the bleeding event, the
relation with bleeding was significant for
heparin (p = 0.04) but failed to reach conven-
tional significance for aPTT (p = 0.08).
A clinically relevant fall in blood leucocyte
count (< 3.0 × 109/l) was observed in three
patients, two of whom were treated with
lefradafiban 60 mg three times daily, and one
with lefradafiban 30 mg three times daily. The
lowest values were 0.9 × 109/l (from 5.9 × 109/l
at baseline), 1.9 × 109/l (from 4.7 × 109/l), and
2.3 × 109/l (from 7.4 × 109/l), observed at 4, 24,
and 48 hours after first study drug dose,
respectively. After discontinuation of study
drug, the leucocyte count in these patients
returned to normal levels without additional
measures within 2–5 days.
Median values for haematological variables
at baseline were within normal limits in all
treatment groups. There was a small decrease
in haemoglobin and thrombocyte concentra-
tions during the trial, which was comparable
among all treatment groups. Median leucocyte
count did not change. Serum concentrations of
thromboplastin, thrombin, and fibrinogen were
not aVected. Median concentrations of bio-
chemical variables at baseline were within the
normal range in all treatment groups and
remained within these limits at 24 and 48
hours.
Discussion
Administration of lefradafiban, an oral prodrug
of the GP IIb/IIIa receptor blocker fradafiban,
resulted in rapid and eVective inhibition of
platelet aggregation in patients with stable cor-
onary artery disease undergoing elective
PTCA. Doses of lefradafiban of 30, 45, and 60
mg three times daily caused a dose dependent
increase in fradafiban plasma concentrations,
an increase in FRO, and inhibition of platelet
aggregation. With the three times daily dosing
regimen, a stable FRO was achieved in each
patient (fig 2). The level of inhibition achieved
in patients who also received aspirin and
heparin was greater than observed in volun-
teers receiving lefradafiban without additional
drug treatment. In the placebo group, platelet
aggregation was already decreased to 60%. In
the phase I studies, inhibition of platelet aggre-
gation of more than 80% was achieved with
lefradafiban doses of 90 mg three times daily.14
In the present study, this was achieved with
45 mg three times daily. This suggests an inter-
action between the GP IIb/IIIa receptor
blocker and aspirin.
As in other studies with GP IIb/IIIa receptor
blockers, bleeding occurred frequently at these
levels of platelet inhibition and was dose
dependent. The incidence of bleeding compli-
cations in the lefradafiban 30 and 45 mg
groups was similar to the rates observed in
studies with other oral GP IIb/IIIa blockers at
similar levels of platelet inhibition,18 19 while
even more bleeding occurred in the highest
dose group (71%). In studies with sibrafiban
and xemilofiban, a gradual increase in bleeding
was observed for higher dose levels with a
greater degree of platelet inhibition.18 19 The
results of the logistic regression analysis in the
present study support these observations, with
an increase in the risk of bleeding by 3% for
every 1% increase in FRO. It should be appre-
ciated that in the majority of cases the bleeding
was insignificant, with a low incidence of minor
bleeding complications (TIMI classification)
and no major bleeding (table 2). Furthermore,
all patients received aspirin and heparin and
underwent invasive coronary procedures. Inter-
actions between the GP IIb/IIIa receptor
blocker abciximab and heparin have been
reported in previous studies.5 6 As demon-
strated in the EPILOG (evaluation of PTCA to
improve long term outcome by c7E3 GP
IIb/IIIa recptor blockade) and EPISTENT
(evaluation of platelet GP IIb/IIIa inhibitor for
stenting) studies, it is likely that a further
reduction in the heparin dose in a weight
adjusted manner might reduce bleeding com-
plications in patients receiving lefradafiban
without decreasing the clinical eYcacy.7 8 Spe-
cial care should be given to the access site of
vascular sheaths. Sheaths should be removed
early (4–6 hours) following the procedure, after
the heparin has been stopped and the activated
clotting time is 175 seconds or less.7 Given the
interpatient variability in the degree of platelet
inhibition observed with oral GP IIb/IIIa
receptor antagonists, another potential strategy
for reducing bleeding complications during
longer term treatment could be to monitor the
degree of platelet inhibition achieved in
individual patients by using a platelet function
bedside assay and to titrate the dose to a target
level of inhibition.20 21
While a gradual dose dependent increase in
bleeding was observed, as in studies with
sibrafiban and xemilofiban,18 19 the relation
between bleeding time and per cent FRO in the
present study suggests a threshold eVect. The
bleeding time was not increased at FRO values
of less than 70%, while a pronounced increase
was observed at higher levels. It should be
Figure 4 Relation between the degree of fibrinogen
receptor occupancy (FRO) and ivy bleeding times at 48
hours after first study drug administration. Each point
represents data from a subject in the lefradafiban 30, 45, or
60 mg group.
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appreciated, however, that measurement of
bleeding time does not reflect a tendency to
spontaneous bleeding in clinical practice.
In three patients receiving lefradafiban, a
clinically significant fall in blood leucocyte
count was observed, although the mean leuco-
cyte count did not change in the overall popu-
lation. Leucopenia from bone marrow depres-
sion has been reported for another antiplatelet
agent (ticlopidine).22 This, however, occurs
mostly after 2–4 weeks of treatment. In the
present study, leucopenia occurred immedi-
ately after the first dose or within two days. In
all three patients, leucocytes returned rapidly
in the peripheral blood after discontinuation of
study drug. Leucopenia had not been observed
in previous studies with lefradafiban in healthy
volunteers and therefore was an unexpected
finding in the present study. Following the
observation of the leucopenia in the three
patients, an amendment was made which
increased the frequency of the haematological
evaluations to monitor the safety of the patients
and investigate the potential underlying patho-
physiological mechanisms. However, no addi-
tional patients experienced this adverse event.
A recently presented second phase II study
with lefradafiban in patients with acute coron-
ary syndromes has confirmed the increased
incidence of leucopenia, or rather neutropenia,
associated with lefradafiban, and has provided
some insight into the pathophysiological
mechanisms involved.23 In accordance with the
present study, the decrease in neutrophils was
characterised by early onset (immediately after
first does of the study drug or within the next
two days) and a rapid recovery after discon-
tinuation of lefradafiban. Based on analysis of
blood and bone marrow samples obtained in
patients with neutropenia in that study, it was
concluded that the observed neutropenia did
not result from bone marrow depression but
rather from a reversible redistribution of
neutrophils by margination or clustering. More
investigations are needed to clarify the precise
mechanisms involved, as well as to determine
the optimum duration of surveillance and the
possible clinical associations.
The clinical benefit of treatment with GP
IIb/IIIa receptor blockers in patients undergo-
ing percutaneous intervention has been estab-
lished by several studies using diVerent
inhibitors.5–10 In the present limited series, all
patients receiving lefradafiban had a successful
PTCA without apparent thrombotic complica-
tions, while acute closure was observed during
PTCA in one patient in the placebo group.
Oral compounds such as lefradafiban oVer an
opportunity for long term treatment with an
eVective platelet aggregation inhibitor, which
may enhance the early benefit of an intravenous
agent and prevent subsequent thrombotic
events in patients at risk.
Three recently presented large clinical trials
have evaluated this concept of long term oral
GP IIb/IIIa inhibition with xemilofiban in
patients after percutaneous coronary interven-
tion (evaluation of oral xemilofiban in control-
ling thrombotic events trial (EXCITE)) and
with orbofiban and sibrafiban in patients after
acute coronary syndromes (orbofiban in pa-
tients with unstable coronary syndromes trial
(OPUS-TIMI-16), and sibrafiban versus aspi-
rin to yield maximum protection from ischemic
heart events post-acute coronary syndromes
trial (SYMPHONY)).24–26 None of the trials
showed a clear treatment benefit of long term
GP IIb/IIIa inhibition, while all three trials
showed a trend towards an increased mortality
in the GP IIb/IIIa inhibitor group.24–26 In this
respect, several points deserve consideration.
First, the patient populations included in these
trials were at relative low risk of recurrent
thrombotic events.24–26 Furthermore, the phar-
macokinetic and pharmacodynamic profile of
these agents is characterised by a steep
dose–response relation and by a short half life
relative to the dosing interval.18 19 25 This may
have caused widely fluctuating inhibition of
platelet aggregation and allowed complete
recovery of platelet function between doses in
some patients, with exposure of activated GP
IIb/IIIa receptors on the platelet’s surface.27
Additionally, recent studies have raised the
possibility that platelet receptor antagonists
may, at low concentrations, alter the steric con-
formation of the GP IIb/IIIa receptor sites and,
paradoxically, enhance the thrombogenicity of
these sites.27 28 Compared with the other oral
agents, the three times daily lefradafiban
dosing regimen may result in higher average
fradafiban concentrations with less peak–
trough fluctuation and more stable levels of
inhibition of platelet aggregation.
It is a challenge to exploit the potential ben-
eficial antithrombotic eVect of oral GP IIb/IIIa
inhibitors in balance with the associated risk of
haemorrhage. Dose titration to a target degree
of platelet inhibition, measured with a rapid
platelet function assay, may improve the overall
safety and eYcacy profile.20 21 To increase the
treatment benefit of (oral) GP IIb/IIIa block-
ers, one may choose to treat only patients who
are at high risk of recurrent thrombotic
complications, such as those who present with
raised troponin concentrations and continue
on medical treatment. These patients may gain
particular benefit from a more aggressive long
term therapeutic approach.29 30
Lefradafiban in doses up to 45 mg three
times daily achieved stable FRO values of more
than 80% in patients with stable coronary
artery disease undergoing elective PTCA, with
acceptable safety during short term treatment.
These doses may therefore be tested in further
studies to assess whether long term treatment
is indeed beneficial in patients with acute cor-
onary syndromes at high risk of thrombotic
complications, without an excess of bleeding
complications.
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Behçet’s disease with a large intracardiac
thrombus: a case report
M Baykan, Sq Çelik, C Erdöl, E C Baykan, I~Durmus¸,
S Bahadir, H Erdöl, C Örem,H Çakirbay
Behçet’s disease is recognised as a chronic multisystem
disorder with vasculitis as its underlying pathological proc-
ess. Cardiac involvement is rare and often associated with
poor prognosis. A case of a 33 year old man with Behçet’s
disease, presenting with a large right ventricle and right
atrial thrombus, is reported. Two dimensional (cross
sectional), colour Doppler, and transoesophageal echo-
cardiography, angiography, computed tomography, and
magnetic resonance imaging were used to diagnose the
disease. With cyclophosphamide and dexamethasone
treatment, the cardiac lesions progressively resolved.
(Heart 2001;85:e7) www.heartjnl.com/cgi/content/full/85/
4/e7
Serious adverse events experienced by patients with
chronic heart failure taking spironolactone
C Berry, J J V McMurray
In patients with chronic heart failure, spironolactone
added to conventional treatment may lead to serious
and, occasionally, fatal hyperkalaemia. In some cases
this seems to happen because spironolactone causes
diarrhoea. Four cases involving men with New York
Heart Association functional class III heart failure
are presented. As these cases revealed, close
monitoring of blood chemistry is mandatory after
starting spironolactone, and patients should be advised
to stop spironolactone immediately if diarrhoea
develops.
(Heart 2001;85:e8) www.heartjnl.com/cgi/content/full/85/
4/e8
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